# EDGAR Filing Document

**Accession Number:** 0001624326
**File Stem:** 0001493152-25-018644
**Filing Date:** 2025-10
**Character Count:** 115475
**Document Hash:** 95698523b5af93a6daf5b854b10e2eb2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-018644.hdr.sgml**: 20251020

**ACCESSION NUMBER**: 0001493152-25-018644

**CONFORMED SUBMISSION TYPE**: PRE 14A

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20251020

**FILED AS OF DATE**: 20251020

**DATE AS OF CHANGE**: 20251020

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PAVmed Inc.
- **CENTRAL INDEX KEY:** 0001624326
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 471214177
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** PRE 14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37685
- **FILM NUMBER:** 251403976

**BUSINESS ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** (212) 949-4319

**MAIL ADDRESS:**
- **STREET 1:** 360 MADISON AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PAXmed Inc.
- **DATE OF NAME CHANGE:** 20141105

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a) of the**

**Securities Exchange Act of 1934**

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☒ Preliminary Proxy Statement

☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐ Definitive Proxy Statement

☐ Definitive Additional Materials

☐ Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12

**PAVMED INC.**

(Name of Registrant as Specified In Its Charter)

**N/A**

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

☒ No fee required. <br> ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Title
 of each class of securities to which transaction applies:

(2) Aggregate
 number of securities to which transaction applies:

(3) Per
 unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
 filing fee is calculated and state how it was determined):

(4) Proposed
 maximum aggregate value of transaction:

(5) Total
 fee paid:

☐ Fee paid previously with preliminary materials.

☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Amount
 Previously Paid:

(2) Form,
 Schedule or Registration Statement No.:

(3) Filing
 Party:

(4) Date
 Filed:

**PRELIMINARY PROXY STATEMENT** 

**SUBJECT TO COMPLETION, DATED OCTOBER 20, 2025**

**PAVMED INC.**

**360 Madison Avenue, 25<sup>th</sup> Floor**

**New York, New York 10017**

**NOTICE OF SPECIAL MEETING OF STOCKHOLDERS**

**TO BE HELD ON DECEMBER 5, 2025**

To the Stockholders of PAVmed Inc.:

NOTICE IS HEREBY GIVEN that a special meeting of stockholders (the "*Special Meeting*") of PAVmed Inc., a Delaware corporation (the "*Company*"), will be held on December 5, 2025 at 10:00 a.m., Eastern time. The Special Meeting will be a virtual meeting. You will be able to attend and participate in the Special Meeting online by visiting https://www.cstproxy.com/pavmed/sm2025. Please see the "*Questions and Answers*" in the accompanying proxy statement for more details.

The Special Meeting is being held for the following purposes:

● *The Reverse Split Proposal*. To approve an amendment to the Company's certificate of incorporation, as amended (the "*Certificate of Incorporation* "), to effect (i) a reverse stock split of the Company's outstanding shares of common stock (the "*Reverse Split*") at a specific ratio, ranging from 1-for-10 to 1-for-30, to be determined by the Company's board of directors (the "*Board*") in its sole discretion, and (ii) an associated reduction in the number of shares of common stock the Company is authorized to issue (the "*Reduction in Authorized Common Stock*") from 250,000,000 shares to 25,000,000 shares.

● *The Adjournment Proposal*. To approve the adjournment of the Special Meeting to the extent there are insufficient votes at the Special Meeting to approve the foregoing proposal.

The Board has set the close of business on October 23, 2025 as the record date for the determination of stockholders who will be entitled to notice of and to vote at the Special Meeting (the "*record date*"). The list of stockholders entitled to vote at the Special Meeting will be available for inspection at the Company's headquarters at least ten days before the Special Meeting.

**Your vote is important no matter how many shares you own.** Whether or not you expect to attend the meeting, please submit a proxy electronically by Internet by following the instructions in these proxy materials or complete, sign and date the accompanying proxy card and return it promptly in the enclosed postage paid reply envelope. Your prompt response is necessary to ensure that your shares are represented at the meeting. You can change your vote and revoke your proxy at any time before the meeting by following the procedures described in the accompanying proxy statement.

---

| |
|:---|
| By Order of the Board of Directors |
| *[●]* |
| Lishan Aklog, M.D. |
| Chairman and Chief Executive Officer |

---

[●], 2025

New York, New York

**Important Notice Regarding the Availability of Proxy Materials for the Special Meeting<br> of Stockholders to be Held on December 5, 2025**:

The Company's Proxy Statement is available at http://www.cstproxy.com/pavmed/sm2025.

**PAVMED INC.<br> 360 Madison Avenue, 25<sup>th</sup> Floor<br> New York, New York 10017**

**PROXY STATEMENT<br> FOR<br> SPECIAL MEETING OF STOCKHOLDERS<br> TO BE HELD ON DECEMBER 5, 2025**

_______________

**INTRODUCTION**

The Company is providing this proxy statement in connection with the solicitation by the Board of proxies to be voted at the Special Meeting to be held on December 5, 2025, at 10:00 a.m., Eastern time, and any adjournment or postponement thereof. The Special Meeting will be a virtual meeting. You will be able to attend and participate in the Special Meeting online by visiting https://www.cstproxy.com/pavmed/sm2025. Please see the "*Questions and Answers*" below for more details.

Capitalized terms used but not defined in this proxy statement have the meanings given to them in the accompanying notice.

This proxy statement and the accompanying proxy card are being mailed or made available to stockholders beginning on or around [●], 2025 in connection with the solicitation of proxies by the Board.

**QUESTIONS & ANSWERS**

**When and where will the meeting take place?**

The Special Meeting will be held on December 5, 2025, at 10:00 a.m., Eastern time, solely over the Internet by means of a live audio webcast. The Company will not conduct the meeting in-person.

Stockholders participating in the Special Meeting will be able to listen only and will not be able to speak during the webcast. However, in order to maintain the interactive nature of the Special Meeting, virtual attendees will be able to:

● vote via the Special Meeting webcast; and

● submit questions or comments to the Company's officers during the Special Meeting via the Special Meeting webcast.

Shareholders may submit questions or comments during the meeting through the Special Meeting webcast by typing in the "Submit a question" box.

**What proposals are being presented for a stockholder vote at the Special Meeting?**

There are two proposals being presented for stockholder vote at the Special Meeting:

● to approve an amendment to the Company's Certificate of Incorporation, to effect (i) the Reverse Split of the Company's outstanding shares of common stock at a specific ratio, ranging from 1-for-10 to 1-for-30, to be determined by the Board in its sole discretion, and (ii) the associated Reduction in Authorized Common Stock from 250,000,000 shares to 25,000,000 shares (which is sometimes called the "*Reverse Split Proposal*" herein); and

● to approve the adjournment of the Special Meeting to the extent there are insufficient proxies at the Special Meeting to approve the foregoing proposal (which is sometimes called the "*Adjournment Proposal*" herein).

The effectuation of the Reverse Split is conditioned on the Company obtaining the consent of the holder of its Series C Preferred Stock (as defined in "*Description of Capital Stock*" below).

Stockholders will also consider any other business as may properly come before the Special Meeting or any adjournment or postponement thereof.

**Why is the Special Meeting being held?**

The Board believes that it is in the best interest of the Company's stockholders to effect the Reverse Split in order to increase the per share trading price of the common stock, for two reasons:

● On January 23, 2025, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ()"*Nasdaq*") notifying the Company that, for the prior 30 consecutive business days (through January 22, 2025), the closing bid price of the common stock had been below the minimum of $1 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The letter stated that the Company would be afforded an initial 180-day period (until July 22, 2025) to regain compliance. The letter also stated that, in the event the Company did not regain compliance within the initial 180-day period, the Company might be eligible for an additional 180-day period to do so. Although the Company did not regain compliance within the initial 180-day period, Nasdaq determined that the Company was eligible for the additional 180-day period (until January 19, 2026). In order to regain compliance, the closing bid price of the common stock must be at least $1 for a minimum of ten consecutive business days ending on or before such date. The Board approved the Reverse Split in an effort to increase the closing bid price of the common stock to the level required for continued listing on Nasdaq. If the closing bid price is not maintained at the necessary level, the Company's securities will be subject to delisting from Nasdaq.

● The Board believes that the Reverse Split will make the common stock more attractive to a broader range of institutional and other investors, as the Company has been advised that the current per share trading price of the common stock may affect its acceptability to certain institutional investors, professional investors and other members of the investing public.

To obtain stockholder approval of the amendment effecting the Reverse Split and the Reduction in Authorized Common Stock, as required under the Delaware General Corporation Law (the "*DGCL*"), the Company called the Special Meeting. For more information on the reasons for the Reverse Split and the Reduction in Authorized Common Stock, see the discussion under "*The Reverse Split Proposal—Reasons for the Reverse Split Proposal*" below.

**What are the recommendations of the Board?**

The Board recommends that you vote:

● "FOR" the Reverse Split Proposal; and

● "FOR" the Adjournment Proposal.

**Who is entitled to vote?**

The holders of the Company's common stock and the Company's Series C convertible preferred stock (the "*Series C Preferred Stock*") at the close of business on the record date, October 23, 2025, are entitled to vote at the Special Meeting. Holders of the common stock have one vote for each share that they own on such date. Holders of the Series C Preferred Stock have one vote for each share of common stock issuable upon conversion of the Series C Preferred Stock that they own on such date (subject to the beneficial ownership limitations set forth therein). As of the record date, [●] shares of common stock were outstanding (inclusive of shares underlying unvested restricted stock awards) and [●] shares of Series C Preferred Stock were outstanding (which were convertible into [●] shares of common stock, after taking into account the beneficial ownership limitation set forth therein).

**What is the difference between a record holder and a beneficial owner?**

If your shares are registered in your name with the Company's transfer agent, Continental Stock Transfer and Trust Company, then you are considered the "record holder" for those shares. If you are the record holder of your shares, you have the right to vote your shares by proxy or to attend the meeting and vote via the Special Meeting webcast.

If your shares are held through a bank, broker or other nominee, then you are considered to hold your shares in "street name." While you are the "beneficial owner" of those shares, you are not considered the record holder. As the beneficial owner of the shares, you have the right to instruct your bank, broker or other nominee how to vote your shares. However, since you are not the record holder of your shares, you may not vote these shares at the Special Meeting unless you obtain a "legal proxy" from the stockholder of record.

**How do I submit my vote?**

*Record Owners*. Record holders can vote by the following methods:

● *By Attending the Special Meeting*. You may attend the Special Meeting and vote via the Special Meeting webcast.

● *By Proxy via the Internet*. You may vote by proxy via the Internet. The proxy card enclosed with this proxy statement provides instructions for submitting a proxy electronically by Internet.

● *By Proxy via the Mail*. You may vote by proxy by completing the enclosed proxy card and returning it in the postage-paid return envelope.

 

*Beneficial Owners*. Beneficial owners of shares held in street name may instruct their bank, broker or other nominee how to vote their shares. Beneficial owners should refer to the materials provided to them by their nominee for information on communicating these "voting instructions." Beneficial owners may not vote their shares at the Special Meeting unless they obtain a legal proxy from the stockholder of record and follow the instructions set forth below for attending the Special Meeting.

**What does it mean to vote by proxy?**

When you vote "by proxy," you grant another person the power to vote stock that you own. If you vote by proxy in accordance with this proxy statement, you will have designated the following individuals as your proxy holders for the Special Meeting: Lishan Aklog, M.D., the Company's Chief Executive Officer and Chairman of the Board; and Dennis McGrath, the Company's President and Chief Financial Officer.

Any proxy given pursuant to this solicitation and received in time for the Special Meeting will be voted in accordance with your specific instructions. If you provide a proxy, but you do not provide specific instructions on how to vote on each proposal, the proxy holder will vote your shares "FOR" the Reverse Split Proposal and "FOR" the Adjournment Proposal. With respect to any other proposal that properly comes before the Special Meeting, the proxy holders will vote in their own discretion according to their best judgment, to the extent permitted by applicable laws and regulations.

**How do I attend the Special Meeting?**

The Special Meeting will be a virtual meeting. Any stockholder wishing to attend the Special Meeting must register in advance. To register for and attend the Special Meeting, please follow these instructions as applicable to the nature of your ownership of the Company's capital stock:

*Record Owners.* If you are a record holder, and you wish to attend the Special Meeting, go to https://www.cstproxy.com/pavmed/sm2025, enter the control number you received on your proxy card or notice of the meeting, and click on the "Click here to preregister for the online meeting" link at the top of the page. Immediately prior to the start of the Special Meeting, you will need to log back into the meeting site using your control number. You must register before the meeting starts.

*Beneficial Owners*. Beneficial owners who wish to attend the Special Meeting must obtain a legal proxy from the stockholder of record and e-mail a copy (a legible photograph is sufficient) of their legal proxy to proxy@continentalstock.com. Beneficial owners should contact their bank, broker or other nominee for instructions regarding obtaining a legal proxy. Beneficial owners who e-mail a valid legal proxy will be issued a meeting control number that will allow them to register to attend and participate in the Special Meeting. You will receive an e-mail prior to the meeting with a link and instructions for entering the Special Meeting. Beneficial owners should contact Continental Stock Transfer on or before [●], 2025.

Stockholders will also have the option to listen to the Special Meeting by telephone by calling:

● Within the U.S. and Canada: (800) 450-7155 (toll-free)

● Outside of the U.S. and Canada: (857) 999-9155 (standard rates apply)

The passcode for telephone access is [●]#. You will not be able to vote or submit questions unless you register for and log in to the Special Meeting webcast as described above.

**What happens if I do not provide voting instructions to my bank, broker or other nominee?**

If you are a beneficial owner and do not provide your bank, broker or other nominee with voting instructions and do not obtain a legal proxy, under the rules of various national and regional securities exchanges, the bank, broker or other nominee may generally vote on routine matters but cannot vote on non-routine matters. If the bank, broker or other nominee that holds your shares does not receive instructions from you on how to vote your shares on a non-routine matter, the bank, broker or other nominee will inform the inspector of election that it does not have the authority to vote on this matter with respect to your shares. This is generally referred to as a "broker non-vote."

The Company expects that the Reverse Split Proposal and the Adjournment Proposal will be considered routine proposals. If they are treated as routine matters as expected, broker non-votes should not occur with respect to these matters in connection with the Special Meeting.

**How do I revoke my proxy or voting instructions?**

*Record Owners.* A record holder may revoke his, her or its proxy by (i) submitting a subsequent written notice of revocation that is received by the Company's Secretary at any time prior to the voting at the Special Meeting, (ii) submitting a subsequent proxy prior to the voting at the Special Meeting or (iii) attending the Special Meeting and voting via the Special Meeting webcast. Attendance by a stockholder at the Special Meeting does not alone serve to revoke his or her proxy. Stockholders may send written notice of revocation to the Secretary, PAVmed Inc., 360 Madison Avenue, 25<sup>th</sup> Floor, New York, New York 10017.

*Beneficial Owners.* Beneficial owners should refer to the materials provided to them by their bank, broker or other nominee for information on changing their voting instructions.

**What constitutes a quorum?**

The presence at the meeting, in person or by proxy, of the holders of a majority of the capital stock outstanding and entitled to vote at the meeting, present in person or represented by proxy, will constitute a quorum for the transaction of business.

Abstentions are voted neither "FOR" nor "AGAINST" a matter, but are counted in the determination of a quorum. Similarly, a "broker non-vote" may occur with respect to shares held in street name, when the bank, broker or other nominee is not permitted to vote such stock on a particular matter as described above. The shares subject to a proxy which are not being voted on a particular "non-routine" matter because of a broker non-vote will not be considered shares present and entitled to vote on the matter. These shares, however, may be considered present and entitled to vote on other "routine" matters and will count for purposes of determining the presence of a quorum, unless the proxy indicates that the shares are not being voted on any matter at the Special Meeting, in which case the shares will not be counted for purposes of determining the presence of a quorum.

**How many votes are required to approve each proposal?**

*Reverse Split Proposal*. Approval of the Reverse Split Proposal requires the affirmative vote of a majority of the outstanding shares of the Company's capital stock, represented in person or by proxy at the meeting and entitled to vote on such proposal, and by a majority of the outstanding shares of the Company's common stock, represented in person or by proxy at the meeting and entitled to vote on such proposal. Abstentions, which are considered present and entitled to vote on this matter, will have the same effect as a vote "AGAINST" this proposal. Broker non-votes on this matter, if any, which are not considered present and entitled to vote on this matter, will not have any effect on the vote with respect to this proposal.

*Adjournment Proposal*. The Adjournment Proposal requires the affirmative vote of a majority of the outstanding shares of the Company's capital stock, represented in person or by proxy at the meeting and entitled to vote on such proposal. Abstentions, which are considered present and entitled to vote on this matter, will have the same effect as a vote "AGAINST" this proposal. Broker non-votes on this matter, if any, which are not considered present and entitled to vote on this matter, will not have any effect on the vote with respect to this proposal.

**Will I have dissenters' rights with respect to any of the matters to be presented at the Annual Meeting?**

Neither Delaware law, nor the Company's Certificate of Incorporation or bylaws, provides for appraisal or other similar rights for dissenting stockholders in connection with any of the matters to be presented at the Special Meeting. Accordingly, stockholders will have no right to dissent and obtain payment for their shares.

**Who is paying for this proxy statement and the solicitation of my proxy, and how are proxies solicited?**

Proxies are being solicited by the Board for use at the Special Meeting. The Company's officers and other employees, without additional remuneration, also may assist in the solicitation of proxies in the ordinary course of their employment. The Company also has engaged Sodali & Co. ("*Sodali*") as the Company's proxy solicitor to assist in the solicitation of proxies for the Special Meeting. The Company has agreed to pay Sodali its customary fee. The Company also will reimburse Sodali for reasonable out-of-pocket expenses and will indemnify Sodali and its affiliates against certain claims, liabilities, losses, damages and expenses.

In addition to the use of the mail and the Internet, solicitations may be made personally or by email or telephone, as well as by public announcement. The Company will bear the cost of this proxy solicitation. The Company may also request brokers, dealers, banks and their nominees to solicit proxies from their clients where appropriate, and may reimburse them for reasonable expenses related thereto.

**Who can help answer my questions?**

If you have questions about how to vote or direct a vote in respect of your shares or about the proposals, or if you need additional copies of the proxy statement or proxy card, you may contact Sodali at:

Sodali & Co.<br> 333 Ludlow Street, 5<sup>th</sup> Floor, South Tower<br> Stamford, Connecticut 06902<br> Tel: (800) 662-5200<br> Banks and brokers call: (203) 658-9400<br> Email: PAVM.info@investor.sodali.com

You may also contact the Company at:

PAVmed Inc.<br> 360 Madison Avenue, 25<sup>th</sup> Floor<br> New York, New York 10017

**THE REVERSE SPLIT PROPOSAL**

On October 20, 2025, the Board unanimously adopted and declared the advisability of an amendment to the Company's Certificate of Incorporation to effect (i) the Reverse Split of the Company's common stock at a specific ratio, ranging from 1-for-10 and 1-for-30, to be determined by the Board in its sole discretion, and (ii) the associated Reduction in Authorized Common Stock from 250,000,000 to 25,000,000 shares. To obtain stockholder approval of the amendment, as required under the DGCL, the Board further directed that the amendment be considered for approval at a special meeting of the Company's stockholders. Accordingly, at the Special Meeting, stockholders will vote on a proposal to approve the amendment effecting the Reverse Split and the Reduction in Authorized Common Stock.

By approving this proposal, the Company's stockholders will be deemed to have approved multiple amendments to the Company's Certificate of Incorporation, each effecting the Reverse Split at one of the whole number ratios between 1-for-10 and 1-for-30, inclusive, and the Reduction in Authorized Common Stock. The Board will determine the ratio of the Reverse Split by choosing which amendment to file with the Delaware Secretary of State. Upon such filing, the amendments effecting the Reverse Split at the other ratios will be deemed abandoned, such that the Board may effect only one Reverse Split. The Board also reserves the right to abandon the amendments in their entirety at any time, if the Board determines, in its sole discretion, that the Reverse Split and the Reduction in Authorized Common Stock are no longer in the best interests of the Company and its stockholders.

The effectuation of the Reverse Split is conditioned on the Company obtaining the consent of the holder of its Series C Preferred Stock (as defined in "*Description of Capital Stock*" below).

A consolidated form of certificate of amendment effecting the Reverse Split and the Reduction in Authorized Common Stock is attached as *Annex A* to this proxy statement.

**General Description of the Reverse Split Proposal**

Approval of the Reverse Split Proposal will authorize the Company to effect a Reverse Split of its common stock at a whole number ratio between 1-for-10 and 1-for-30, inclusive, with the specific ratio to be determined by the Board in its sole discretion.

The Company believes that the availability to the Board of a range of approved ratios will provide the Company with the flexibility to implement the Reverse Split in a manner designed to maximize the anticipated benefits for the Company and its stockholders. In determining which ratio to implement, if any, following the receipt of stockholder approval, the Board may consider, among other things:

● the historical trading price and trading volume of the common stock;

● the then-prevailing trading price and trading volume of the common stock and the anticipated impact of the Reverse Split on the trading market for the common stock; and

● prevailing general market and economic conditions.

The Reverse Stock Split will affect all holders of the common stock uniformly and will not affect any stockholder's percentage ownership interest in the Company, except to the extent that the Reverse Split would result in any holder of the common stock receiving fractional shares. Stockholders will not receive fractional shares of common stock in connection with the Reverse Split. Instead, stockholders who otherwise would have been entitled to a fraction of a share as a result of the Reverse Split will receive in lieu thereof one additional whole share.

The table set forth below under *"—Effect on Shares of Common Stock*" presents, for illustrative purposes only, the approximate number of shares of common stock the Company expects to be outstanding after giving effect to the Reverse Split, at three different Reverse Split ratios within the range set forth above, in each case assuming 26,678,690 shares of common stock outstanding immediately prior to the Reverse Split (which is the amount outstanding, inclusive of shares underlying unvested restricted stock awards, as of October 15, 2025) and without giving effect to the issuance of shares of common stock in lieu of fractional shares.

The Reverse Split itself will not impact the market value of the Company as a whole, although the market value of the common stock may move up or down once the Reverse Split is effective. The Company does not expect the Reverse Split itself to have any economic effect on the Company's common stockholders, preferred stockholders, debt holders or option holders, except to the extent the Reverse Split will result in issuance of additional shares of common stock in lieu of fractional shares.

The determination of the specific ratio for the Reverse Split will not affect the number of shares of common stock the Company is authorized to issue after the Reverse Split. Regardless of the ratio, as a result of the Reduction in Authorized Common Stock, the Company will be authorized to issue 25,000,000 shares of common stock after the Reverse Split.

The Board does not intend for the Reverse Split to be the first step in a series of plans or proposals to effect a "going private transaction" within the meaning of Rule 13e-3 of the Exchange Act.

**Reasons for the Reverse Split Proposal**

***Reverse Split***

 ****

The Board believes that it is in the best interest of the Company's stockholders to effect the Reverse Split in order to increase the per share trading price of the common stock, for the following reasons.

*Regain Nasdaq Compliance*. The common stock is publicly traded and listed on Nasdaq under the symbol PAVM. On January 23, 2025, the Company received a letter from the Nasdaq Listing Qualifications Department notifying the Company that, for the prior 30 consecutive business days (through January 22, 2025), the closing bid price of the common stock had been below the minimum of $1 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The letter stated that the Company would be afforded an initial 180-day period (until July 22, 2025) to regain compliance. The letter also stated that, in the event the Company did not regain compliance within the initial 180-day period, the Company might be eligible for an additional 180-day period to do so. Although the Company did not regain compliance within the initial 180-day period, Nasdaq determined that the Company was eligible for the additional 180-day period (until January 19, 2026). In order to regain compliance, the closing bid price of the common stock must be at least $1 for a minimum of ten consecutive business days ending on or before such date. The Board approved the Reverse Split in an effort to increase the closing bid price of the common stock to the level required for continued listing on Nasdaq. If the closing bid price is not maintained at the necessary level, the Company's securities will be subject to delisting from Nasdaq.

*Facilitate Investment*. The Company believes that the Reverse Split will make the common stock more attractive to a broader range of institutional and other investors, as the Company has been advised that the current per share trading price of the common stock may affect its acceptability to certain institutional investors, professional investors and other members of the investing public. Many brokerage houses and institutional investors have internal policies and practices that either prohibit them from investing in low-priced stocks or tend to discourage individual brokers from recommending low-priced stocks to their customers. In addition, some of those policies and practices may function to make the processing of trades in low-priced stocks economically unattractive to brokers.

Reducing the number of outstanding shares of the common stock through the Reverse Split is intended, absent other factors, to increase the per share trading price of the common stock. However, other factors, such as the Company's financial results, market conditions and market perception of the Company's business may adversely affect the per share trading price of the common stock. As a result, there can be no assurance that the Reverse Split, if implemented, will result in the intended benefits described above, that the per share trading price of the common stock will increase as expected following the Reverse Split or that the per share trading price of the common stock will not decrease in the future.

***Reduction in Authorized Common Stock***

 ****

As a matter of Delaware law, the implementation of the Reverse Split does not require a reduction in the total number of authorized shares of common stock. However, the amendment to the Company's Certificate of Incorporation effecting the Reverse Stock Split also will effect the Reduction in Authorized Common Stock from 250,000,000 shares to 25,000,000 shares.

While the Reduction in Authorized Common Stock will reduce the number of shares authorized for issuance on an absolute basis, it may have the effect of increasing the number of shares of common stock authorized for issuance relative to the number of shares outstanding, if the ratio for the Reverse Split is greater than 1-for-10. The Board believes a relative increase in the number of shares of common stock authorized for issuance in these circumstances is in the best interests of the Company and its stockholders.

A relative increase in these circumstances will enable the Company to meet its obligations under its outstanding options, warrants and convertible securities, and its equity compensation plans, while retaining flexibility to respond to future business needs and opportunities. For example, the shares may be used for additional equity awards to the Company's employees, for financing the Company's business, for acquiring other businesses, or for forming strategic partnerships and alliances. While the Company from time to time explores opportunities for strategic transactions that could result in the issuance of common stock, including equity capital raises, as they arise or as the Company's needs require, the Company has no current agreement or commitment to issue additional shares of its common stock, except for issuances of common stock upon the exercise of its outstanding options and warrants and the conversion of its outstanding convertible preferred stock and notes.

**Risks of the Reverse Split Proposal**

***Risks Related to the Reverse Split***

 ****

*The Company cannot assure you that the Reverse Split will increase the per share trading price of the common stock as expected or that it will have the desired effects.* 

 

If the Reverse Split is implemented, the Board expects that the Reverse Split will increase the per share trading price of the common stock. However, the effect of the Reverse Split upon the market price of the common stock cannot be predicted with any certainty.

 

The history of similar reverse stock splits for companies in similar circumstances is varied. It is possible that the per share trading price of the common stock may decline from the proportionately adjusted price promptly after the Reverse Split. In addition, after the Reverse Split, the per share trading price of the common stock may decrease due to factors unrelated to the Reverse Split. The trading price of the common stock after the Reverse Split will be based on numerous factors unrelated to the number of shares outstanding, such as the Company's financial results, market conditions and market perception of the Company's business.

As a result, it is possible that (i) the per share bid price of the common stock after the Reverse Split will not remain in excess of the $1 minimum under the Nasdaq Listing Rules, (ii) the Reverse Split will not result in a per share trading price that would attract institutional investors, professional investors and other members of the investing public or improve the economics of processing trades in the common stock, (iii) if the trading price declines from the proportionately adjusted price promptly after the Reverse Split, the total market capitalization of the Company shortly after the Reverse Split will be lower than it would have been absent the Reverse Split, and (iv) it will be more difficult for the Company to achieve the market capitalization it attained in the recent past, because the absolute per share trading price will need to be proportionately larger.

*Even if the Company regains compliance with Nasdaq's minimum bid price requirement, the Company cannot assure you that it will remain in compliance with this requirement or Nasdaq's other continued listing requirements.*

 

Even if the bid price per share of the common stock exceeds $1 per share for the period of time required to regain compliance with Nasdaq's minimum bid price requirement, the Company may be delisted due to a failure to meet this requirement in the future or due to a failure to meet the other continued listing requirements, including Nasdaq requirements related to the minimum stockholders' equity, minimum number of shares that must be in the public float and the minimum market value of the public float. A decrease in the outstanding shares and total market capitalization of the Company as a result of the Reverse Split, as described above, may exacerbate this risk.

*The Reverse Split may decrease the liquidity of the common stock.* 

 

The liquidity of the common stock may be negatively impacted by the Reverse Split, given the reduced number of shares that would be outstanding after the Reverse Split, particularly if the increased per share trading price resulting from the Reverse Split is not maintained. In addition, the Reverse Split will increase the number of stockholders who own "odd lots" of fewer than 100 shares of the common stock. Brokerage commission and other costs of transactions in odd lots are generally higher than the costs of transactions of more than 100 shares of common stock. Accordingly, the Reverse Split may not achieve the desired results of increasing marketability of the common stock as described above.

***Risks Related to the Reduction in Authorized Common Stock***

 ****

*Future issuances of common stock by the Company may have an adverse effect on the market price of the common stock.*

While the Reduction in Authorized Common Stock will reduce the number of shares authorized for issuance on an absolute basis, it may have the effect of increasing the number of shares of common stock authorized for issuance relative to the number of shares outstanding, if the ratio for the Reverse Split is greater than 1-for-10. The Company may issue a substantial number of these shares of the common stock under its outstanding options, warrants, preferred stock and convertible notes, as well as under its existing equity compensation plan and employee stock purchase plan. In addition, the Company may issue additional shares of common stock in future financings. Any of the foregoing issuances will dilute the Company's existing stockholders. Furthermore, the trading price of the common stock could decline as a result of sales of such shares of common stock, or the perception that such sales could occur.

**Mechanics of the Reverse Split**

***Effective Time***

 ****

The effective time of the Reverse Split, if approved by stockholders and implemented by the Company, will be the date and time set forth in the certificate of amendment that is filed with the Delaware Secretary of State. It is expected that such filing will take place promptly following the Special Meeting, assuming the stockholders approve the amendment. The effective time could occur as soon as the 10<sup>th</sup> day immediately following the Special Meeting. The exact timing of the filing of the amendment will be determined by the Board based on its evaluation as to when such action will be the most advantageous to the Company and its stockholders.

***Fractional Shares***

 ****

Stockholders will not receive fractional shares of common stock in connection with the Reverse Split. Instead, stockholders who otherwise would have been entitled to a fraction of a share as a result of the Reverse Split will receive in lieu thereof one additional whole share.

***Record and Beneficial Stockholders***

 ****

Stockholders of record who hold their shares electronically in book entry form do not need to take any action to receive their post-Reverse Split shares of common stock. Stockholders of record who hold their shares of common stock electronically in book-entry form will receive a transaction statement at their address of record as soon as practicable after the effective date of the Reverse Split, indicating the number of post-Reverse Split shares of common stock they own.

Stockholders of record who hold their shares in certificate form will receive a letter of transmittal as soon as practicable after the effective date of the Reverse Split. The Company's transfer agent will act as "exchange agent" for the purpose of implementing the exchange of such old stock certificates. Holders of old stock certificates will be asked to surrender their stock certificates to the exchange agent in accordance with the procedures set forth in the letter of transmittal. Upon delivery of the old stock certificates, together with the other required documentation properly completed and executed in accordance with the procedures set forth in the letter of transmittal, the Company's transfer agent will issue the applicable post-Reverse Split shares in book-entry form, as evidenced by a transaction statement that will be sent to the stockholder's address of record. From the effective time of the Reverse Split until the surrender of the old stock certificates as described herein, the old stock certificates will be deemed to represent the number of whole shares resulting from the Reverse Split.

STOCKHOLDERS SHOULD NOT DESTROY ANY STOCK CERTIFICATES AND SHOULD NOT SUBMIT ANY CERTIFICATES UNTIL THEY ARE REQUESTED TO DO SO.

Beneficial stockholders who hold their shares of common stock in "street name" through a bank, broker or other nominee should note that, although the Company intends to treat beneficial stockholders in the same manner as stockholders of record, such banks, brokers or other nominees may have different procedures for processing the Reverse Split than those put in place by the Company for stockholders of record. If you hold your shares in "street name" and if you have questions in this regard, you are encouraged to contact your bank, broker or other nominee.

**Principal Effects of the Reverse Split Proposal**

***Effect on the Common Stock***

 ****

If the Reverse Split is approved by the stockholders and implemented by the Company, each stockholder will own a reduced number of shares of the common stock. Except for adjustments that may result from the treatment of fractional shares as described above, the proposed reverse split will affect all stockholders uniformly. The proportionate voting rights and other rights and preferences of the holders of the common stock will not be affected by the Reverse Split (other than as a result of the treatment of fractional shares). For example, a holder of 2% of the voting power of the outstanding shares of the common stock immediately prior to the Reverse Split would continue to hold 2% of the voting power of the outstanding shares of the common stock immediately after such Reverse Split. The number of stockholders of record also will not be affected by the Reverse Split.

The determination of the specific ratio for the Reverse Split will not affect the number of shares of common stock the Company is authorized to issue after the Reverse Split. Regardless of the ratio, as a result of the Reduction in Authorized Common Stock, the Company will be authorized to issue 25,000,000 shares of common stock after the Reverse Split.

The following table presents, for illustrative purposes only, the approximate number of shares of common stock the Company expects to be outstanding, number of shares of common stock the Company will be authorized to issue, and certain related information, after giving effect to the Reverse Split and Reduction in Authorized Common Stock, at three different Reverse Split ratios within the range set forth above, in each case assuming 26,678,690 shares of common stock outstanding immediately prior to the Reverse Split (which is the amount outstanding, inclusive of shares underlying unvested restricted stock awards, as of October 15, 2025) and without giving effect to the issuance of shares of common stock in lieu of fractional shares.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As of**<br> **Oct. 15, 2025** | **After 1-for-10 Reverse Split** | **After 1-for-20 Reverse Split** | **After 1-for-30 Reverse Split** |
| Authorized Common Stock <sup>(1)</sup> | 250000000 | 25000000 | 25000000 | 25000000 |
| Issued and Outstanding Common Stock | 26678690 | 2667869 | 1333935 | 889290 |
| Number of Shares of Common Stock Issuable Pursuant to Existing Arrangements<sup>(2)</sup> | 29648119 | 2964812 | 1482406 | 988271 |
| Remaining Number of Shares of Common Stock Authorized | 193673191 | 19367319 | 22183659 | 23122439 |
| Price Per Share<sup>(3)</sup> | $0.5313 | $5.313 | $10.626 | $15.939 |

---

________________

&nbsp;&nbsp;&nbsp;&nbsp;(1) The
 determination of the specific ratio for the Reverse Split will not affect the number of shares
 of common stock the Company is authorized to issue after the Reverse Split. Regardless of
 the ratio, as a result of the Reduction in Authorized Common Stock, the Company will be authorized
 to issue 25,000,000 shares of common stock after the Reverse Split.

&nbsp;&nbsp;&nbsp;&nbsp;(2) The
 number of shares of stock issuable pursuant to existing arrangements as of October 15, 2025
 (without giving effect to the Reverse Split) includes the following:

● 1,382,560 shares issuable upon exercise of stock options at a weighted average exercise price of $11.79 per share;

● 99,959 shares issuable upon conversion of the Series B Preferred Stock (as defined in "*Description of Capital Stock*" below), assuming for the purposes hereof that all outstanding shares are converted in full at the conversion price of $45.00 per share;

● 21,643,768 shares issuable upon conversion of the Series C Preferred Stock (as defined in "*Description of Capital Stock*" below), assuming the Series C Preferred Stock was converted in full on such date at the voluntary fixed conversion price of $1.068 per share (without taking into account the beneficial ownership limitation set forth therein); and

● 6,521,832 shares were issuable upon conversion of the September 2022 Senior Convertible Note (as defined in "*Description of Capital Stock*" below), assuming the September 2022 Senior Convertible Note was converted in full on such date at the voluntary fixed conversion price of $1.068 per share (without taking into account the beneficial ownership limitation set forth therein).

The number of shares of common stock to be issued under the Series B Preferred Stock may be greater than this amount, because dividends on the Series B Preferred Stock may be settled, at the Company's option, through any combination of the issue of additional shares of Series B Preferred Stock, the issue of shares of common stock, and the payment of cash, as described below.

The number of shares of common stock to be issued under the Series C Convertible Stock may be substantially greater than the amount above, if certain triggering events occur, because in such cases the number of shares issued will be determined based on the then current market price (but in any event not more than voluntary fixed conversion price per share or less than a floor price), and as a result of the capitalization of dividends on the Series C Preferred Stock.

The number of shares of common stock to be issued under the September 2022 Senior Convertible Note may be substantially greater than the amount above, if the Company makes the amortization payments of principal and interest in shares of common stock, because in such cases (and in certain other cases as set forth therein) the number of shares issued will be determined based on the then current market price (but in any event not more than voluntary fixed conversion price per share or less than a floor price).

The Company cannot predict the market price of the common stock at any future date, and therefore, the Company is unable to accurately forecast or predict the total amount of shares that ultimately may be issued under the Series C Preferred Stock and the September 2022 Senior Convertible Note. In addition, the number of shares issued under the Series C Preferred Stock and the September 2022 Senior Convertible Note may be substantially greater if the Company voluntarily lowers the conversion price, which the Company is permitted to do pursuant to the terms thereof. The voluntary fixed conversion price of the Series C Preferred Stock is also subject to adjustment for subsequent equity issuances.

Furthermore, the number of shares of stock issuable pursuant to existing arrangements, as set forth above, does not include 1,029,964 shares of common stock reserved for issuance, but not subject to outstanding awards, under the 2014 Plan (as defined in "*Description of Capital Stock*" below) and 306,530 shares of common stock reserved for issuance under the ESPP (as defined in "*Description of Capital Stock*" below). It also does not reflect future increases in the size of the 2014 Plan and the ESPP that may occur on an annual basis pursuant to the terms of such plans. The number of shares of stock issuable pursuant to existing arrangements, as set forth above, also does not include shares issuable pursuant the sales agreement between the Company and Maxim (as defined in "*Description of Capital Stock*" below), pursuant to which the Company may offer and sell, from time to time, up to $2,880,000 in shares of common stock to or through Maxim in an "at the market" offering. See the information under "*Description of Capital Stock*" below.

For more information on the anticipated effect of the Reverse Split on these existing arrangements, see "—*Effect on Outstanding Derivative Securities and Equity Compensation Plans*."

&nbsp;&nbsp;&nbsp;&nbsp;(3) The
 price per share indicated reflects solely the application of the applicable Reverse Split
 ratio to the closing price of the common stock on October 15, 2025.

The common stock currently is registered under Section 12(b) of the Exchange Act and is subject to the periodic reporting and other requirements of the Exchange Act. The Reverse Split will not affect the registration of the common stock under the Exchange Act.

Immediately after the Reverse Split and Reduction in Authorized Common Stock, the common stock will continue to be listed on Nasdaq under the symbol PAVM, although it is likely that Nasdaq would add the letter "D" to the end of the trading symbol for a period of twenty trading days after the effective date of the Reverse Split to indicate that the Reverse Split had occurred. There can be no assurance that the Company will regain compliance with Nasdaq's continued listing requirements, including the minimum bid price requirement, or that the common stock will continue to be listed on the Nasdaq Capital Market.

After the effective date of the Reverse Split, the common stock will have a new Committee on Uniform Securities Identification Procedures ("*CUSIP*") number, which is the number used to identify the common stock.

***Effect on Outstanding Derivative Securities and Equity Compensation Plans***

 ****

The Reverse Split will require that proportionate adjustments be made to the conversion rate, the per share exercise price and the number of shares issuable upon the exercise or conversion of the Company's outstanding derivative securities, based on the Reverse Split ratio determined by the Board. The adjustments to the Company's outstanding derivative securities will result in approximately the same aggregate price being required to be paid upon exercise of such exercisable securities, and approximately the same value of shares of common stock being delivered upon such conversion of such convertible securities, immediately following the Reverse Split as was the case immediately preceding the Reverse Split.

Under the terms of the 2014 Plan, upon the implementation of a reverse stock split, the compensation committee of the Board may, in its sole discretion, equitably adjust the awards under the 2014 Plan in order to prevent dilution or enlargement of the benefits available under the 2014 Plan (including as to the number of shares subject to the award and the exercise price), equitably adjust the aggregate number of shares reserved for issuance under the 2014 Plan, and equitably adjust the aggregate number of shares that may be issued pursuant to incentive stock options under the 2014 Plan. In accordance with this provision, upon implementation of the Reverse Split, the compensation committee of the Board has determined to proportionately adjust the per share exercise price and the number of shares issuable upon the exercise of employee stock options under the 2014 Plan as described above, and to proportionately adjust the aggregate number of shares reserved for issuance and the aggregate number of shares that may be issued pursuant to incentive stock options, based on the Reverse Split ratio determined by the Board. Restricted stock awards under the 2014 Plan will be treated like all other shares of outstanding common stock.

Under the terms of the ESPP, upon the implementation of a reverse stock split, the compensation committee of the Board must equitably and proportionately adjust the number of shares of common stock that thereafter may be made the subject of options under the ESPP (including the specific limits, maximums and other numbers of shares set forth in the ESPP), to the extent necessary to preserve (but not increase) the level of incentives intended by the ESPP and the then-outstanding options. In accordance with this provision, upon implementation of the Reverse Split, the compensation committee of the Board has determined to proportionately adjust the maximum aggregate number of shares that may be delivered pursuant to options under the ESPP, as well as all limits and other share amounts specifically set forth in the ESPP.

The table below presents, for illustrative purposes only, the anticipated effect of the Reverse Split on the Company's outstanding derivative securities and equity compensation plans, at three different Reverse Split ratios within the range set forth above:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **As of**<br> **Oct. 15, 2025** | **After 1-for-10 Reverse Split** | **After 1-for-20 Reverse Split** | **After 1-for-30 Reverse Split** |
| *Employee Stock Options:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Shares Issuable Upon Exercise | 1382560 | 138256 | 69128 | 46085 |
| &nbsp;&nbsp;&nbsp;Weighted Average Exercise Price Per Share | $11.79 | $117.90 | $235.80 | $353.70 |
| *Series B Preferred Stock:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Shares Issuable Upon Conversion in Full | 99959 | 9996 | 4998 | 3332 |
| &nbsp;&nbsp;&nbsp;Conversion Price Per Share | $45.00 | $450.00 | $900.00 | $1350.00 |
| &nbsp;&nbsp;&nbsp;*Series C Preferred Stock:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Shares Issuable Upon Conversion in Full<sup>(1)</sup> | 21643768 | 2164377 | 1082189 | 721459 |
| &nbsp;&nbsp;&nbsp;Conversion Price Per Share | $1.068 | $10.68 | $21.36 | $32.04 |
| *September 2022 Senior Convertible Note:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Shares Issuable Upon Conversion of Outstanding Principal and Interest<sup>(2)</sup> | 6521832 | 652184 | 326092 | 217395 |
| &nbsp;&nbsp;&nbsp;Fixed Conversion Price Per Share | $1.068 | $10.68 | $21.36 | $32.04 |
| *2014 Plan:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Aggregate Remaining Shares Reserved for Issuance<sup>(3)</sup> | 1029964 | 102996 | 51498 | 34332 |
| *ESPP:* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Aggregate Remaining Shares Reserved for Issuance<sup>(3)</sup> | 306530 | 30653 | 15326 | 10217 |

---

________________

&nbsp;&nbsp;&nbsp;&nbsp;(1) Assumes
 the Series C Preferred Stock was converted in full on such date at the voluntary fixed conversion
 price set forth in the table (without taking into account the beneficial ownership limitation
 set forth therein). The number of shares of common stock to be issued under the Series C
 Preferred Stock may be substantially greater than this amount, as discussed in "*Description of Capital Stock*" below.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Assumes
 the September 2022 Senior Convertible Note was converted in full on such date at the voluntary
 fixed conversion price set forth in the table (without taking into account the beneficial
 ownership limitation set forth therein). The number of shares of common stock to be issued
 under the September 2022 Senior Convertible Note may be substantially greater than this amount,
 as discussed in "*Description of Capital Stock*" below.

&nbsp;&nbsp;&nbsp;&nbsp;(3) The
 number of shares of stock reserved for issuance does not reflect future increases in the
 size of the 2014 Plan and the ESPP that may occur on an annual basis pursuant to the terms
 of such plans. See the information under "*Description of Capital Stock* "
 below.

***Effect on the Preferred Stock***

 ****

The Reverse Split and the Reduction in Authorized Common Stock will have no effect on the number of outstanding shares of Series B Preferred Stock or Series C Preferred Stock and no effect on the number of shares of preferred stock the Company is authorized to issue (or on the number of such shares designated as Series B Preferred Stock). The Reverse Split will cause the conversion price and the number of shares issuable upon conversion of the Series B Preferred Stock and the Series C Preferred Stock to be proportionately adjusted as described above.

**Accounting Consequences**

Upon implementation of the Reverse Split, the par value per share of the common stock will remain unchanged at $0.001 per share. As a result, on the effective date of the Reverse Split, the stated capital on the Company's consolidated balance sheet attributable to the common stock par value will be reduced proportionally from its present amount, based on the Reverse Split ratio selected by the Board, with a corresponding equal increase to the common stock additional paid-in capital. The loss per share and net book value per share will each be higher given the reduced number of shares of common stock issued and outstanding. The shares of common stock held in treasury, if any, will also be reduced proportionately based on the Reverse Split ratio selected by the Board. If the Reverse Split is implemented, it will reduce the number of shares of common stock outstanding, and will require that proportionate adjustments be made to the conversion rate, the per share exercise price and the number of shares issuable upon the exercise or conversion of the Company's outstanding derivative securities, in accordance with the Reverse Split ratio determined by the Board. Retroactive presentation will be given to all share numbers in the financial statements, and accordingly all amounts including per share amounts will be shown on a post-Reverse Split basis. The Company does not anticipate any other accounting consequences would arise as a result of the Reverse Split.

**Material Federal U.S. Income Tax Consequences of the Reverse Split**

The following is a summary of certain material U.S. federal income tax consequences of the Reverse Split to the Company's stockholders. The summary is based on the Internal Revenue Code of 1986, as amended (the "*Code*"), applicable Treasury Regulations promulgated thereunder, judicial authority and current administrative rulings and practices as in effect on the date of this proxy statement, all of which are subject to change or differing interpretations which could alter the tax consequences described below, possibly with retroactive effect. The Company has not sought and will not seek an opinion of counsel or a ruling from the Internal Revenue Service regarding the federal income tax consequences of the Reverse Split. This discussion only addresses stockholders who hold common stock as "capital assets" as defined in the Code (generally, property held for investment). It does not purport to be a complete summary of all potential tax consequences and does not address stockholders subject to special tax treatment under the Code, including, without limitation, financial institutions, tax-exempt organizations, insurance companies, dealers in securities, foreign stockholders, stockholders who hold their pre-reverse stock split shares as part of a straddle, hedge or conversion transaction, and stockholders who acquired their pre-reverse stock split shares pursuant to the exercise of employee stock options or otherwise as compensation. If a partnership (or other entity treated as a partnership for U.S. federal income tax purposes) is the beneficial owner of the common stock, the U.S. federal income tax treatment of a partner in the partnership will generally depend on the status of the partner and the activities of the partnership. Accordingly, partnerships (and other entities treated as partnerships for U.S. federal income tax purpose) holding the common stock and the partners in such entities should consult their own tax advisors regarding the U.S. federal income tax consequences of the proposed Reverse Split to them. In addition, the following discussion does not address the tax consequences of the Reverse Split under state, local and foreign tax laws. Furthermore, the following discussion does not address any tax consequences of transactions effectuated before, after or at the same time as the Reverse Split, whether or not they are in connection with the Reverse Split. Each stockholder should consult his, her or its own tax advisor as to the particular facts and circumstances that may be unique to such stockholder and also as to any estate, gift, state, local or foreign tax considerations arising out of the Reverse Split.

In general, the federal income tax consequences of a Reverse Split will vary among stockholders depending upon whether they receive an additional whole share in lieu of a fractional share or solely a reduced number of shares of common stock in exchange for their old shares of common stock. The Company believes that because the Reverse Split is not part of a plan to increase periodically a stockholder's proportionate interest in the Company's assets or earnings and profits, the Reverse Split should have the following federal income tax effects. The Company intends for the Reverse Split to qualify as a "reorganization" pursuant to Section 368(a)(1)(E) of the Code that should qualify as a "recapitalization" for U.S. federal income tax purposes. However, the Company has not sought and will not seek any ruling from the Internal Revenue Service regarding any matters relating to the transaction, and as a result, there can be no assurance that the Internal Revenue Service will not assert, or that a court would not sustain, a contrary position, in which case the consequences of the transaction could be materially different from those described herein. Provided that the Reverse Split qualifies as a "recapitalization," a stockholder who receives solely a reduced number of shares of common stock will not recognize gain or loss, based upon the Reverse Split ratio. In the aggregate, such a stockholder's basis in the reduced number of shares of common stock will equal the stockholder's basis in its old shares of common stock and such stockholder's holding period in the reduced number of shares will include the holding period in its old shares exchanged. The Treasury Regulations provide detailed rules for allocating the tax basis and holding period of shares of common stock surrendered in a recapitalization to shares received in the recapitalization. Stockholders of the common stock acquired on different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares.

As discussed above, the Company will not issue fractional shares in connection with the Reverse Split. Instead, stockholders who would be entitled to receive fractional shares because they hold a number of shares not evenly divisible by the Reverse Split ratio would automatically be entitled to receive an additional fraction of a share of common stock to round up to the next whole share of common stock. The U.S. federal income tax consequences of the receipt of such an additional fraction of a share are not clear. The Internal Revenue Service may take the position that a stockholder who, pursuant to the proposed Reverse Split, receives an additional whole share in lieu of a fractional share should be treated as though the receipt by it of an additional portion of a share results in a distribution, that it results in gain, or that no income or gain is recognized. Any income or gain recognized should not exceed the excess, if any, of the fair market value of such whole share over the fair market value of the fractional share to which the stockholder otherwise was entitled. Stockholders are urged to consult their own tax advisors regarding the tax consequences to them of the issuance of an additional whole share in lieu of a fractional share in the Reverse Split.

The Company will not recognize any gain or loss as a result of the proposed Reverse Split.

A stockholder of the common stock may be subject to information reporting and backup withholding on any additional share issued in lieu of a fractional share in connection with the Reverse Split. A stockholder of the common stock will be subject to backup withholding if such stockholder is not otherwise exempt and such stockholder does not provide its taxpayer identification number in the manner required or otherwise fails to comply with backup withholding tax rules. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be refunded or allowed as a credit against a stockholder's U.S. federal income tax liability, if any, provided the required information is timely furnished to the Internal Revenue Service. Stockholders of the common stock should consult their own tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption.

THE PRECEDING DISCUSSION IS INTENDED ONLY AS A SUMMARY OF CERTAIN FEDERAL U.S. INCOME TAX CONSEQUENCES OF THE REVERSE SPLIT AND DOES NOT PURPORT TO BE A COMPLETE ANALYSIS OR DISCUSSION OF ALL POTENTIAL TAX EFFECTS RELEVANT THERETO. YOU SHOULD CONSULT YOUR OWN TAX ADVISORS AS TO THE PARTICULAR FEDERAL, STATE, LOCAL, FOREIGN AND OTHER TAX CONSEQUENCES OF THE REVERSE SPLIT IN LIGHT OF YOUR SPECIFIC CIRCUMSTANCES.

**Required Vote, Appraisal Rights and Recommendation**

Approval of the Reverse Split Proposal requires the affirmative vote of a majority of the outstanding shares of the Company's capital stock, represented in person or by proxy at the meeting and entitled to vote on such proposal, and by a majority of the outstanding shares of the Company's common stock, represented in person or by proxy at the meeting and entitled to vote on such proposal. Abstentions, which are considered present and entitled to vote on this matter, will have the same effect as a vote "AGAINST" this proposal. Broker non-votes on this matter, if any, which are not considered present and entitled to vote on this matter, will not have any effect on the vote with respect to this proposal.

The effectuation of the Reverse Split is conditioned on the Company obtaining the consent of the holder of its Series C Preferred Stock (as defined in "*Description of Capital Stock*" below).

Neither the DGCL, nor the Company's Certificate of Incorporation or bylaws, provides for appraisal or other similar rights for dissenting stockholders in connection with the Reverse Split Proposal. Accordingly, stockholders will have no right to dissent and obtain payment for their shares.

THE BOARD RECOMMENDS THAT YOU VOTE "FOR" THE REVERSE SPLIT PROPOSAL.

**THE ADJOURNMENT PROPOSAL**

**General Description of the Adjournment Proposal**

At the Special Meeting, stockholders will vote on a proposal to approve the adjournment of the Special Meeting to the extent there are insufficient proxies at the Special Meeting to approve the Reverse Split Proposal.

If this proposal is adopted, the Board will have the discretion to adjourn the Special Meeting to a later date or dates to permit further solicitation of proxies. It is possible for the Company to obtain sufficient votes to approve the Adjournment Proposal but not receive sufficient votes to approve the Reverse Split Proposal. In such a situation, the Company could adjourn the meeting for any number of days or hours as permitted under applicable law and attempt to solicit additional votes in favor of such other proposals.

In addition to an adjournment of the Special Meeting upon approval of the Adjournment Proposal, if a quorum is not present at the Special Meeting, the Company's bylaws allow the Special Meeting to be adjourned for the purpose of obtaining a quorum. Any such adjournment may be made without notice, other than the announcement made at the Special Meeting, by the affirmative vote of a majority of the shares of common stock present in person or by proxy and entitled to vote at the Special Meeting. The Board also is empowered under Delaware law to postpone the meeting at any time prior to the meeting being called to order. In such event, the Company would issue a press release and take such other steps as it believes are necessary and practical in the circumstances to inform its stockholders of the postponement.

If the stockholders approve the Adjournment Proposal, and the Special Meeting is adjourned, the Company expects to use the additional time to solicit additional proxies in favor of the Reverse Split Proposal. Among other things, approval of the Adjournment Proposal could mean that, even if a majority of the common stock has been voted against the Reverse Split Proposal, the Company could adjourn the Special Meeting without a vote on such proposal, and seek to convince the holders of those shares to change their votes. Any adjournment of the Special Meeting for the purpose of soliciting additional proxies will allow stockholders who have already sent in their proxies to revoke them at any time prior to the voting on the Reverse Split Proposal.

The Adjournment Proposal will only be presented at the Special Meeting if there are not sufficient votes represented in person or by proxy for the other proposals. If the Adjournment Proposal is presented at the Special Meeting and is not approved, the Company may not be able to adjourn the Special Meeting to a later date. As a result, the Company may be prevented from obtaining approval of the Reverse Split Proposal.

**Required Vote and Recommendation**

Approval of the Adjournment Proposal requires the affirmative vote of a majority of the outstanding shares of the Company's capital stock, represented in person or by proxy at the meeting and entitled to vote on such proposal. Abstentions, which are considered present and entitled to vote on this matter, will have the same effect as a vote "AGAINST" this proposal. Broker non-votes on this matter, if any, which are not considered present and entitled to vote on this matter, will not have any effect on the vote with respect to this proposal.

THE BOARD RECOMMENDS THAT YOU VOTE "FOR" THE ADJOURNMENT PROPOSAL.

**DESCRIPTION OF CAPITAL STOCK**

*The following information does not give effect to the Reverse Stock Split or the Reduction in Authorized Common Stock. For information on the effect of the Reverse Stock Split and the Reduction in Authorized Common Stock, see "The Reverse Split Proposal" above.*

**Authorized and Outstanding Capital Stock**

The Company is authorized to issue 250,000,000 shares of common stock, par value $0.001, and 20,000,000 shares of preferred stock, par value $0.001.

On March 23, 2018, the Company designated 1,800,000 shares of its preferred stock as Series B Convertible Preferred Stock, par value $0.001 per share (the "*Series B Preferred Stock*"). On January 17, 2025, the Company designated 25,000 shares of its preferred stock as Series C Convertible Preferred Stock, par value $0.001 per share (the "*Series C Preferred Stock*").

As of October 15, 2025, 26,678,690 shares of common stock were issued and outstanding. In addition, as of October 15, 2025:

● 1,382,560 shares were issuable upon exercise of stock options at a weighted average exercise price of $11.79 per share;

● 99,959 shares were issuable upon conversion of the Series B Preferred Stock, assuming for the purposes hereof that all outstanding shares are converted in full at the conversion price of $45.00 per share;

● 21,643,768 shares were issuable upon conversion of the Series C Preferred Stock, assuming the Series C Preferred Stock was converted in full on such date at the voluntary fixed conversion price of $1.068 per share (without taking into account the beneficial ownership limitation set forth therein); and

● 6,521,832 shares were issuable upon conversion of the 7.875% Senior Secured Convertible Note due December 2025, originally issued in September 2022 (the "*September 2022 Senior Convertible Note* "), assuming the September 2022 Senior Convertible Note was converted in full on such date at the voluntary fixed conversion price of $1.068 per share (without taking into account the beneficial ownership limitation set forth therein).

The number of shares of common stock to be issued under the Series B Preferred Stock may be greater than this amount, because dividends on the Series B Preferred Stock may be settled, at the Company's option, through any combination of the issue of additional shares of Series B Preferred Stock, the issue of shares of common stock, and the payment of cash, as described below.

The number of shares of common stock to be issued under the Series C Convertible Stock may be substantially greater than the amount above, if certain triggering events occur, because in such cases the number of shares issued will be determined based on the then current market price (but in any event not more than voluntary fixed conversion price per share or less than a floor price), and as a result of the capitalization of dividends on the Series C Preferred Stock.

The number of shares of common stock to be issued under the September 2022 Senior Convertible Note may be substantially greater than the amount above, if the Company makes the amortization payments of principal and interest in shares of common stock, because in such cases (and in certain other cases as set forth therein) the number of shares issued will be determined based on the then current market price (but in any event not more than voluntary fixed conversion price per share or less than a floor price).

The Company cannot predict the market price of the common stock at any future date, and therefore, the Company is unable to accurately forecast or predict the total amount of shares that ultimately may be issued under the Series C Preferred Stock and the September 2022 Senior Convertible Note. In addition, the number of shares issued under the Series C Preferred Stock and the September 2022 Senior Convertible Note may be substantially greater if the Company voluntarily lowers the conversion price, which it is permitted to do pursuant to the terms thereof. The voluntary fixed conversion price of the Series C Preferred Stock is also subject to adjustment for subsequent equity issuances.

Furthermore, the number of shares of common stock issued and outstanding, does not include 1,029,964 shares of common stock reserved for issuance, but not subject to outstanding awards, under the Company's Sixth Amended and Restated Long-Term Incentive Equity Plan (the "*2014 Plan*") and 306,530 shares of common stock reserved for issuance under the Company's Amended and Restated Employee Stock Purchase Plan (the "*ESPP*"). It also does not reflect future increases in the size of the 2014 Plan and the ESPP that may occur on an annual basis pursuant to the terms of such plans. The number of shares of common stock issued and outstanding also does not include shares issuable pursuant the sales agreement between the Company and Maxim Group LLC ("*Maxim*"), pursuant to which the Company may offer and sell, from time to time, up to $2,880,000 in shares of common stock to or through Maxim in an "at the market" offering.

As of October 15, 2025, 1,499,384 shares of Series B Preferred Stock and 21,855 shares of Series C Preferred Stock were issued and outstanding. The Company may issue additional shares of Series B Preferred Stock in settlement of dividends on the issued and outstanding Series B Preferred Stock, as described below.

***Common Stock***

 ****

Holders of common stock are entitled to one vote per share on matters on which the Company's stockholders vote. There are no cumulative voting rights. Subject to any preferential dividend rights of any outstanding shares of preferred stock, holders of common stock are entitled to receive dividends, if declared by the Board, out of funds that the Company may legally use to pay dividends. If the Company liquidates or dissolves, holders of common stock are entitled to share ratably in the Company's assets once its debts and any liquidation preference owed to any then-outstanding preferred stockholders is paid. The Certificate of Incorporation does not provide the common stock with any redemption, conversion or preemptive rights, and there are no sinking fund provisions with respect to the common stock. All shares of common stock that are outstanding are fully-paid and non-assessable.

***Preferred Stock***

 ****

The Certificate of Incorporation authorizes the issuance of blank check preferred stock. Accordingly, the Board is empowered, without stockholder approval, to issue shares of preferred stock with dividend, liquidation, redemption, voting or other rights which could adversely affect the voting power or other rights of the holders of shares of the common stock. In addition, shares of preferred stock could be utilized as a method of discouraging, delaying or preventing a change in control of the Company.

*Series B Preferred Stock*

 

The Series B Preferred Stock has a par value of $0.001 per share, a stated value of $3.00 per share, and is convertible into common stock, as discussed below. The Series B Convertible Preferred stock is senior to the common stock with respect to dividends and assets distributed in liquidation.

The Series B Preferred Stock has no voting rights.

The Series B Preferred Stock provides for dividends at a rate of 8% per annum of the stated value per share. Dividends are payable in arrears on January 1, April 1, July 1, and October 1. Dividends accrue and cumulate whether or not declared by the Board. All accumulated and unpaid dividends compound quarterly at the rate of 8% of the stated value per annum. Prior to October 1, 2021, dividends were payable in additional shares of Series B Preferred Stock. Since October 1, 2021, dividends have been payable at the Company's election in any combination of shares of Series B Preferred Stock, cash or shares of common stock.

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or Deemed Liquidation Event (as defined in the certificate of designations for the Series B Preferred Stock), the holders of shares of Series B Preferred Stock then outstanding shall be entitled to be paid out of the Company's assets available for distribution to its stockholders, before any payment shall be made to the holders of the common stock by reason of their ownership thereof, an amount per share equal to the greater of (i) the stated value of the Series B Preferred Stock, plus any dividends accrued but unpaid thereon, or (ii) such amount per share as would have been payable had all shares of Series B Preferred Stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event.

At the holders' election, a share of Series B Preferred Stock is convertible into a number of shares of common stock determined by dividing the stated value of such share of Series B Preferred Stock by the conversion price. The conversion price is $45.00 per share, subject to adjustment for stock dividends, stock splits or similar events affecting the common stock. Accordingly, as of October 15, 2025, every 15 shares of Series B Preferred Stock is convertible into one share of common stock. The Series B Preferred Stock shall not be redeemed for cash and under no circumstances shall the Company be required to net cash settle the Series B Preferred Stock.

All shares of Series B Preferred Stock that are outstanding are fully-paid and non-assessable.

*Series C Preferred Stock*

The Series C Preferred Stock has a par value of $0.001 per share, a stated value of $1,000 per share, and is convertible into common stock, as discussed below. The Series C Preferred Stock is pari passu with the Series B Convertible Preferred Stock and is senior to all of the Company's other equity securities.

The Series C Preferred Stock is entitled to vote with the holders of shares of the common stock, voting together as one class, on all matters in which the holders of the preferred stock are permitted to vote with the class of shares of common stock pursuant to applicable law, on an as-converted basis (subject to certain limitations, including the beneficial ownership limitation described below).

Holders of the Series C Preferred Stock are entitled to a preferred dividend at a rate of 7.875% per annum, payable quarterly in arrears.

Upon liquidation, a holder of Series C Preferred Stock will be entitled to receive in cash out of the Company's assets, before any amount is paid to the holders of any of shares of the common stock, but pari passu with the holders of any Series B Preferred Stock then outstanding, an amount per share equal to the greater of (A) the sum of (i) 110% of the stated value (plus any accrued and unpaid dividends or other amounts then payable thereon) of such share of Series C Preferred Stock then outstanding and (ii) a ratable portion of 100% of the stated value (plus any accrued and unpaid dividends or other amounts then payable thereon) of the Series B Preferred Stock then outstanding and (B) the amount per share such holder would receive if such holder converted such share of Series C Preferred Stock into common stock immediately prior to the date of such payment.

Each share of Series C Preferred Stock, plus accrued and unpaid dividends thereon, is convertible at any time, in whole or in part, at the holder's option, into shares of common stock at an initial voluntary fixed conversion price of $1.068 per share, subject to certain adjustments.

In addition, at any time following the occurrence of certain triggering events, a holder of shares of the Series C Preferred Stock will have the right to elect to convert shares of Series C Preferred Stock into common stock at an alternate conversion price equal to the lower of: (i) the fixed conversion price then in effect, and (ii) the lowest of (A) 80% of the VWAP of the common stock as of the trading day immediately preceding the delivery or deemed delivery of the applicable notice of conversion, (B) 80% of the VWAP of the common stock as of the trading day of the delivery or deemed delivery of the applicable notice of conversion, and (C) 80% of the average VWAP of the common stock for each of the two trading days with the lowest VWAP of the common stock during the ten consecutive trading day period ending and including the trading day immediately prior to the delivery or deemed delivery of the applicable notice of conversion, but in the case of clause (ii), not less than $0.2136 (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events). The triggering events include events that would constitute an event of default under the September 2022 Senior Convertible Note, in addition to the Company's failure to complete a Qualified Company Optional Redemption by March 31, 2025. The principal consequence of a triggering event (other than a bankruptcy-related triggering event) will be to give the holder the right to elect an alternate conversion as described above. In addition, the occurrence of a triggering event (other than the Company's failure to complete a Qualified Company Optional Redemption by March 31, 2025) will result in an increase to the dividend rate and limit the Company's right to redeem the Series C Preferred Stock. A triggering event (other than a bankruptcy-related triggering event) will not otherwise accelerate any financial or other obligation on the Company's part in respect of the Series C Preferred Stock.

In addition to customary adjustments for stock splits, combinations, reclassifications and similar events, if the Company grants, issues or sells (or enters into any agreement to grant, issue or sell) or is deemed to have granted, issued or sold, any shares of its common stock, for consideration per share less than the fixed conversion price then in effect, then immediately after such issuance, the fixed conversion price will be reduced to an amount equal to such lower price.

The Company has the right to redeem all, but not less than all, of the shares of Series C Preferred Stock at a redemption price equal to 132.5% of the aggregate stated value of the Series C Preferred Stock plus all accrued and unpaid dividends and other amounts then payable thereon. The Company also has an additional one-time right to redeem a portion of the shares of Series C Preferred Stock with an aggregate stated value of at least $5 million at the same redemption price. Such a partial redemption is sometimes referred to as a "*Qualified Company Optional Redemption*."

Upon certain changes in control of the Company, a holder of the Series C Preferred Stock will have the right to require the Company to redeem all, or any portion, of the holder's shares of Series C Preferred Stock at a price equal to 132.5% of the stated value of the Series C Preferred Stock (plus any accrued and unpaid dividends or other amounts then payable thereon) or, if greater, an amount determined pursuant to the certificate of designations based on the then-current market price or the consideration payable in the change of control transaction, whichever is higher.

A holder may not convert any of the shares of Series C Preferred Stock, to the extent that, after giving effect to such conversion, such holder (together with certain of its affiliates and other related parties) would beneficially own in excess of 9.99% (the "*Maximum Percentage*") of the shares of the common stock outstanding immediately after giving effect to such conversion. The Holder may from time to time increase or decrease the Maximum Percentage; provided that in no event could the Maximum Percentage exceed 9.99%, provided, further, that any such increase would not be effective until the 61st day after delivery of a notice to the Company of such increase.

The Company and its subsidiaries (other than Lucid Diagnostics Inc.) are subject to certain customary affirmative and negative covenants regarding the rank of the Series C Preferred Stock, the incurrence of indebtedness, the existence of liens, the repayment of indebtedness and the making of investments, the payment of cash in respect of dividends, distributions or redemptions, the transfer of assets, the maturity of other indebtedness, transactions with affiliates and the ability to complete stock splits, among other customary matters. The Company also is subject to a financial covenant requiring that the Company maintains its cash flow on a break-even basis.

All shares of Series C Preferred Stock that are outstanding are fully-paid and non-assessable.

**Dividends**

The Company has not paid any cash dividends on the common stock to date. Any future decisions regarding dividends will be made by the Board. The Company does not anticipate paying dividends in the foreseeable future but expects to retain earnings to finance the growth of its business. The Board has complete discretion on whether to pay dividends, subject to the restrictions set forth in the Convertible Notes and related documents and in the certificate of designations for the Series B Preferred Stock. Even if the Board decides to pay dividends, the form, frequency and amount will depend upon the Company's future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors the Board may deem relevant. In addition, the September 2022 Senior Convertible Note and the Series C Preferred Stock contain customary restrictions on the payment of dividends on our common stock. The Series B Preferred Stock is senior to our common stock in right of payment of dividends.

**Anti-Takeover Provisions**

Provisions of the DGCL and the Company's Certificate of Incorporation and bylaws could make it more difficult to acquire the Company by means of a tender offer, a proxy contest or otherwise, or to remove incumbent officers and directors. These provisions, summarized below, are expected to discourage certain types of coercive takeover practices and takeover bids that the Board may consider inadequate and to encourage persons seeking to acquire control of the Company to first negotiate with the Board. The Company believes that the benefits of increased protection of the Company's ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure the Company outweigh the disadvantages of discouraging takeover or acquisition proposals because, among other things, negotiation of these proposals could result in improved terms for the Company's stockholders.

*Delaware Anti-Takeover Statute*. The Company is subject to Section 203 of the DGCL, an anti-takeover statute. In general, Section 203 of the DGCL prohibits a publicly-held Delaware corporation from engaging in a "business combination" with an "interested stockholder" for a period of three years following the time the person became an interested stockholder, unless the business combination or the acquisition of shares that resulted in a stockholder becoming an interested stockholder is approved in a prescribed manner. Generally, a "business combination" includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. Generally, an "interested stockholder" is a person who, together with affiliates and associates, owns (or within three years prior to the determination of interested stockholder status did own) 15% or more of a corporation's voting stock. The existence of this provision would be expected to have an anti-takeover effect with respect to transactions not approved in advance by the Board, including discouraging attempts that might result in a premium over the market price for the shares of common stock held by the Company's stockholders.

*Classified Board*. The Board is divided into three classes. The number of directors in each class is as nearly equal as possible. Directors elected to succeed those directors whose terms expire are elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election. The existence of a classified board may extend the time required to make any change in control of the Board when compared to a corporation with an unclassified board. It may take two annual meetings for the Company's stockholders to effect a change in control of the Board, because in general less than a majority of the members of the Board will be elected at a given annual meeting. Because the Board is classified and the Certificate of Incorporation does not otherwise provide, under the DGCL, the Company's directors may only be removed for cause.

*Vacancies in the Board of Directors*. The Company's Certificate of Incorporation and bylaws provide that, subject to limitations, any vacancy occurring in the Board for any reason may be filled by a majority of the remaining members of the Board then in office, even if such majority is less than a quorum. Each director elected to fill a vacancy resulting from the death, resignation or removal of a director shall hold office until the expiration of the term of the director whose death, resignation or removal created the vacancy.

*Advance Notice of Nominations and Shareholder Proposals*. The Company's stockholders are required to provide advance notice and additional disclosures in order to nominate individuals for election to the Board or to propose matters that can be acted upon at a stockholders' meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer's own slate of directors or otherwise attempting to obtain control of the Company.

*Special Meetings of Stockholders*. Under the Company's bylaws, special meetings of stockholders may be called by the directors, or the president or the chairman, and shall be called by the secretary at the request in writing of stockholders owning a majority in amount of the entire capital stock of the corporation outstanding and entitled to vote.

*No Cumulative Voting*. The DGCL provides that stockholders are denied the right to cumulate votes in the election of directors unless a corporation's certificate of incorporation provides otherwise. The Company's Certificate of Incorporation does not provide for cumulative voting.

**Limitation on Directors' Liability and Indemnification**

The Certificate of Incorporation and the Company's bylaws provide that no director of the Company will be personally liable to the Company or any of its stockholders for monetary damages arising from the director's breach of fiduciary duty as a director. However, this does not apply (i) for any breach of the director's duty of loyalty to the Company or tis stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) for liability under Section 174 of the DGCL, or (iv) for any transaction from which the director derived an improper personal benefit.

The Certificate of Incorporation provides that all directors shall be entitled to be indemnified by the Company to the fullest extent permitted by law and the Company's bylaws contain comparable provisions. The Certificate of Incorporation also provides that the Company shall pay the expenses incurred by its directors in defending any action for which indemnification may be available, upon receipt of an undertaking by or on behalf of such director to repay such amount if it shall ultimately be determined that he or she is not entitled to be indemnified. The Company has entered into, and intend to continue to enter into, separate indemnification agreements with its directors, in addition to the indemnification provided for in the Certificate of Incorporation and the Company's bylaws. The Company also maintains directors' and officers' liability insurance.

These provisions could have the effect of reducing the likelihood of derivative litigation against the Company's directors and may discourage or deter the Company's stockholders or management from bringing a lawsuit against the Company's directors for breach of their duty of care, even though such an action, if successful, might otherwise have benefited the Company and its stockholders.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or person controlling us pursuant to the foregoing provisions, the Company has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is therefore unenforceable.

**Market**

The common stock is traded on the Nasdaq Capital Market under the symbols PAVM.

**Transfer Agent and Registrar**

The transfer agent and registrar for the common stock is Continental Stock Transfer & Trust Company located at 1 State Street, 30th Floor, New York, NY 10004.

**SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS**

The following table sets forth information regarding the beneficial ownership of the Company's common stock as of October 15, 2025, by:

● each person known by the Company to be the beneficial owner of more than 5% of the Company's outstanding shares of common stock;

● each of the Company's officers and directors; and

● all of the Company's officers and directors as a group.

The beneficial ownership of each person was calculated based on 26,678,690 shares of the Company's common stock outstanding as of October 15, 2025 (inclusive of shares underlying unvested restricted stock awards). Except as otherwise indicated, the Company believes all persons named in the table below have sole voting and investment power with respect to all the shares of common stock beneficially owned by them.

---

| | | |
|:---|:---|:---|
| **Name and Address of Beneficial Owner<sup>(1)</sup>** | **Amount**<br> **and**<br> **Nature of**<br> **Beneficial Ownership** | **Percent**<br> **of Class** |
| *Directors and Officers:* |  |  |
| &nbsp;&nbsp;&nbsp;Lishan Aklog, M.D. | 572083<sup>(2)</sup> | 2.1% |
| &nbsp;&nbsp;&nbsp;Dennis M. McGrath | 240507<sup>(3)</sup> | \* |
| &nbsp;&nbsp;&nbsp;Shaun M. O'Neil | 212605<sup>(4)</sup> | \*% |
| &nbsp;&nbsp;&nbsp;Michael A. Gordon | 176666<sup>(5)</sup> | \*% |
| &nbsp;&nbsp;&nbsp;Michael J. Glennon | 308079<sup>(6)</sup> | 1.2% |
| &nbsp;&nbsp;&nbsp;Sundeep Agrawal, M.D. | 268445<sup>(7)</sup> | 1.0% |
| &nbsp;&nbsp;&nbsp;Timothy E. Baxter | 252833<sup>(8)</sup> | 1.0% |
| &nbsp;&nbsp;&nbsp;Ronald M. Sparks | 284334<sup>(9)</sup> | 1.1% |
| &nbsp;&nbsp;&nbsp;Debra J. White | 254499<sup>(10)</sup> | 1.0% |
| All directors and executive officers as a group (nine individuals) | 2575051 | 9.8% |
| *5% Stockholders:* |  |  |
| &nbsp;&nbsp;&nbsp;Tasso Partners LLC | 2574350<sup>(11)</sup> | 9.6% |
| &nbsp;&nbsp;&nbsp;Ayrton Capital LLC | [●]<sup>(12)</sup> | [●]% |
| &nbsp;&nbsp;&nbsp;Sargent Investment Group, LLC | 1006300<sup>(13)</sup> | 3.8% |

---

_______________

\* Represents less than one percent of class.

&nbsp;&nbsp;&nbsp;&nbsp;(1) The
 business address of each of the individuals is 360 Madison Avenue, 25<sup>th</sup> Floor,
 New York, New York 10017, unless otherwise indicated.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Includes:
 (i) 297,105 shares of common stock held by Pavilion Venture Partners LLC ("PVP"),
 of which Dr. Aklog is a member and sole manager, and, accordingly, over which he is deemed
 to have voting and dispositive power; (ii) 1,333 shares of common stock held by HCFP/AG LLC,
 of which Dr. Aklog is a co-manager, and, accordingly, over which he is deemed to have voting
 and dispositive power; (iii) 78,724 shares of common stock held by Dr. Aklog and his
 children; (iv) 150,000 shares subject to a restricted stock award granted under the
 2014 Plan to Dr. Aklog with the award vesting on May 20, 2028; and (v) 44,921
 shares of common stock issuable upon the potential exercise of stock options granted to Dr.
 Aklog which have vested or are expected to vest within sixty days as of October 15, 2025.
 Notwithstanding the foregoing, Dr. Aklog disclaims beneficial ownership of the shares of
 common stock held by PVP and HCFP/AG LLC, except to the extent of his proportionate pecuniary
 interest therein.

&nbsp;&nbsp;&nbsp;&nbsp;(3) Includes
 50,834 shares of common stock held by Mr. McGrath; 150,000 shares subject to
 a restricted stock award granted under the 2014 Plan to Mr. McGrath with the award vesting
 on May 20, 2028; and 39,673 shares of common stock issuable upon the potential
 exercise of stock options granted to Mr. McGrath which have vested and are expected to vest
 within sixty days as of October 15, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(4) Includes
 17,932 shares of common stock held by Mr. O'Neil; 150,000 shares subject
 to a restricted stock award granted under the 2014 Plan to Mr. O'Neil with the award
 vesting on May 20, 2028; and 44,673 shares of common stock issuable upon the
 potential exercise of stock options granted to Mr. O'Neil which have vested and are
 expected to vest within sixty days as of October 15, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(5) Includes
 150,000 shares subject to a restricted stock award granted under the 2014 Plan to
 Mr. Gordon with the award vesting on May 20, 2028; and 26,666 shares of common
 stock issuable upon the potential exercise of stock options granted to Mr. Gordon which have
 vested and are expected to vest within sixty days as of October 15, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(6) Includes
 16,667 shares of common stock; 65,000 shares subject to a restricted stock award granted
 under the 2014 Plan to Mr. Glennon with the award vesting on November 30, 2026; 150,000
 shares subject to a restricted stock award granted under the 2014 Plan to Mr. Glennon with
 the award vesting on May 20, 2028; and 81,412 shares of common stock issuable
 upon the potential exercise of stock options granted to Mr. Glennon which have vested and
 are expected to vest within sixty days as of October 15, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(7) Includes
 12,195 shares subject to a restricted stock award granted under the 2014 Plan to Dr. Agrawal
 with the award vesting one-third on June 30, 2024 and the balance vesting ratably on a quarterly
 basis commencing September 30, 2024 with a final quarterly vesting date of June 30, 2026;
 150,000 shares subject to a restricted stock award granted under the 2014 Plan to
 Dr. Agrawal with the award vesting on May 20, 2028; and 106,250 shares of common stock
 issuable upon the potential exercise of stock options granted to Dr. Agrawal which have vested
 and are expected to vest within sixty days as of October 15, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(8) Includes
 65,000 shares subject to a restricted stock award granted under the 2014 Plan to Mr. Baxter
 with the award vesting on November 30, 2026; 150,000 shares subject to a restricted
 stock award granted under the 2014 Plan to Mr. Baxter with the award vesting on May
 20, 2028; and 37,833 shares of common stock issuable upon the potential exercise
 of stock options granted to Mr. Baxter which have vested and are expected to vest within
 sixty days as of October 15, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(9) Includes
 65,000 shares subject to a restricted stock award granted under the 2014 Plan to Mr. Sparks
 with the award vesting on November 30, 2026; 150,000 shares subject to a restricted
 stock award granted under the 2014 Plan to Mr. Sparks with the award vesting on May 20,
 2028; and 69,334 shares of common stock issuable upon the potential exercise of
 stock options granted to Mr. Sparks which have vested and are expected to vest within sixty
 days as of October 15, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(10) Includes
 65,000 shares subject to a restricted stock award granted under the 2014 Plan to Ms. White
 with the award vesting on November 30, 2026; 150,000 shares subject to a restricted
 stock award granted under the 2014 Plan to Ms. White with the award vesting on May
 20, 2028; and 39,499 shares of common stock issuable upon the potential exercise
 of stock options granted to Ms. White which have vested and are expected to vest within sixty
 days as of October 15, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(11) Dana
 Carrera may be deemed to beneficially own the shares of common stock held by Tasso Capital,
 LLC. The business address of each of Tasso Capital, LLC and Ms. Carrera is P.O. Box 503,
 Rumson, New Jersey 07760. The information relating to Tasso Capital, LLC and Ms. Carrera
 is derived from a Schedule 13G filed on February 28, 2025.

(12) Includes shares of common stock beneficially owned by Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B. Each of Ayrton Capital LLC and Waqas Khatri may be deemed to beneficially own the shares of common stock held by Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B. Represents (i) [●] shares of common stock held by such persons; and (ii) [●] shares of common stock issuable on the conversion of certain convertible notes and Series C Preferred Stock held by such persons. The issuable shares of common stock related to the conversion of the convertible notes and the Series C Preferred Stock are subject to a 9.99% beneficial ownership blocker. The business address of each Ayrton Capital LLC and Mr. Khatri is 55 Post Rd West, 2nd Floor, Westport, CT 06880. The business address of Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B is Suite #7 Grand Pavilion Commercial Centre, 802 West Bay Road, Grand Cayman, P.O. Box 10250, Cayman Islands. The information relating to Ayrton Capital LLC is derived in part from a Schedule 13G/A filed on February 13, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;(13) The
 business address of each of Sargent Investment Group, LLC is 4920 Elm Street, Suite 305,
 Bethesda, Maryland 20814. The information relating to Sargent Investment Group, LLC is derived
 from a Schedule 13G filed on August 14, 2025.

**STOCKHOLDER PROPOSALS AND NOMINATIONS**

The Company intends to hold its 2026 annual meeting of stockholders on June 18, 2026. A proposal that a stockholder intends to present at the 2026 annual meeting of stockholders and wishes to be considered for inclusion in the Company's proxy materials must be received no later than December 31, 2025. All proposals must comply with Rule 14a-8 under the Exchange Act.

The Company's bylaws contain provisions intended to promote the efficient functioning of stockholder meetings. Some of the provisions require advance notice to the Company of stockholder proposals or director nominations to be considered at an annual meeting. Under the Company's bylaws, in order to properly bring stockholder proposals or director nominations before an annual meeting, even if the stockholder does not intend to include such proposal in the Company's proxy materials, the stockholder must deliver written notice of such proposal or nomination to the Secretary not less than 60 days nor more than 90 days prior to the meeting; provided, however, that in the event that less than 70 days' notice or prior public disclosure of the date of the annual meeting is given or made to stockholders, notice by a stockholder, to be timely, must be received no later than the close of business on the 10th day following the day on which such notice of the date of the annual meeting was mailed or such public disclosure was made. Accordingly, for the 2025 annual meeting of stockholders, this notice must be received no earlier than March 20, 2026 and no later than April 19, 2026. A notice of a stockholder proposal or director nomination must include the information set forth in the Company's bylaws. Stockholder proposals and director nominations should be addressed to Secretary, PAVmed Inc., 360 Madison Avenue, 25th Floor, New York, New York 10017.

**HOUSEHOLDING OF PROXY MATERIALS**

The Securities and Exchange Commission has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for proxy statements with respect to two or more stockholders sharing the same address by delivering a single proxy statement addressed to those stockholders. This process, which is commonly referred to as "householding," potentially means extra convenience for stockholders and cost savings for companies.

A number of brokers with account holders who are stockholders of the Company will be "householding" the Company's proxy materials. A single set of the Company's proxy materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker that they will be "householding" communications to your address, "householding" will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in "householding" and would prefer to receive a separate set of the Company's proxy materials at no charge, please notify your broker, bank or other nominee, if you are a beneficial owner, or direct a request to the Company, if you are a holder of record. Holders of record may make send a request in writing to PAVmed Inc., 360 Madison Avenue, 25th Floor, New York, New York 10017, or may make a request by telephone at (917) 813-1828. The Company undertakes to deliver promptly, upon any such written or verbal request, a separate copy of the Company's proxy materials to a stockholder at a shared address to which a single copy of these documents was delivered. Stockholders who currently receive multiple copies of the Company's proxy materials at their address and would like to request "householding" of their communications should contact their broker, bank or other nominee, or contact the Company at the above address or phone number.

**OTHER MATTERS**

The Company does not intend to bring before the Special Meeting any matters other than those specified in the Notice of the Special Meeting, and the Company does not know of any business which persons other than the Board intend to present at the Special Meeting. Should any business requiring a vote of the stockholders, which is not specified in the notice, properly come before the Special Meeting, the proxy holders specified in this proxy statement and in the accompanying proxy card intend to vote the shares represented by them in accordance with their best judgment.

**SOLICITATION OF PROXIES**

Proxies are being solicited by the Board for use at the Special Meeting. The Company's officers and other employees, without additional remuneration, also may assist in the solicitation of proxies in the ordinary course of their employment. The Company also has engaged Sodali as the Company's proxy solicitor to assist in the solicitation of proxies for the Special Meeting. The Company has agreed to pay Sodali its customary fee. The Company also will reimburse Sodali for reasonable out-of-pocket expenses and will indemnify Sodali and its affiliates against certain claims, liabilities, losses, damages and expenses.

In addition to the use of the mail and the Internet, solicitations may be made personally or by email or telephone, as well as by public announcement. The Company will bear the cost of this proxy solicitation. The Company may also request brokers, dealers, banks and their nominees to solicit proxies from their clients where appropriate, and may reimburse them for reasonable expenses related thereto.

If you have questions about how to vote or direct a vote in respect of your shares or about the proposals, or if you need additional copies of the proxy statement or proxy card, you may contact Sodali at:

Sodali & Co.

333 Ludlow Street, 5<sup>th</sup> Floor, South Tower

Stamford, Connecticut 06902

Tel: (800) 662-5200

Banks and brokers call: (203) 658-9400

Email: PAVM.info@investor.sodali.com

You may also contact the Company at:

PAVmed Inc.

360 Madison Avenue, 25<sup>th</sup> Floor

New York, New York 10017

Attention: Secretary

_______________

---

| |
|:---|
| By Order of the Board of Directors |
| *[●]* |
| Lishan Aklog, M.D. |
| Chairman and Chief Executive Officer |

---

[●]

New York, New York

**ANNEX A**

**CERTIFICATE OF AMENDMENT**

**OF**

**CERTIFICATE OF INCORPORATION**

**OF**

**PAVMED INC.**

_______________

**Pursuant to Section 242 of the**

**General Corporation Law of Delaware**

_______________

The undersigned Chairman and Chief Executive Officer of PAVmed Inc. (the "Corporation") does hereby certify:

FIRST: The name of the Corporation is PAVmed Inc.

SECOND: Upon the filing and effectiveness (the "Effective Time") pursuant to the General Corporation Law of the State of Delaware (the "DGCL") of this Certificate of Amendment of Certificate of Incorporation of the Corporation, each [●] ([●])<sup>1</sup> shares of the Corporation's Common Stock, par value $0.001 per share, issued and outstanding immediately prior to the Effective Time shall automatically be combined into one (1) validly issued, fully paid and non-assessable share of Common Stock without any further action by the Corporation or the holder thereof, subject to the treatment of fractional share interests as described below (the "Reverse Split"). No fractional shares shall be issued at the Effective Time and, in lieu thereof, each stockholder who would otherwise would have been entitled to receive a fractional share as a result of the Reverse Split shall instead be entitled to receive one additional whole share. Each certificate that immediately prior to the Effective Time represented shares of Common Stock ("Old Certificates"), shall thereafter represent that number of shares of Common Stock into which the shares of Common Stock represented by the Old Certificate shall have been combined, subject to the elimination of fractional share interests as described above.

THIRD: Upon the Effective Time, the Certificate of Incorporation of the Corporation is hereby amended by deleting the first paragraph of Article FOURTH in its entirety and by substituting the following new first paragraph of Article FOURTH in lieu thereof:

"FOURTH: The total number of shares of all classes of capital stock which the Corporation shall have authority to issue is 45,000,000 of which 25,000,000 shares shall be Common Stock of the par value of $.001 per share and 20,000,000 shares shall be Preferred Stock of the par value of $.001 per share."

FOURTH: This Certificate of Amendment of Certificate of Incorporation of the Corporation shall become effective as of [●], 202[●] at [●] [a.m./p.m.].

FIFTH: The foregoing amendment to the Corporation's certificate of incorporation was duly adopted in accordance with the provisions of Sections 242 of the Delaware General Corporation Law.

_______________

<sup>1</sup> A whole number between 10 and 30, inclusive, as determined by the Board in its sole discretion.

IN WITNESS WHEREOF, the undersigned has signed this certificate of amendment on this [●] day of [●], 202[●].

  <br> Lishan Aklog, M.D. <br> Chairman and Chief Executive Officer

![](proxy_001.jpg)

![](proxy_002.jpg)